Japan's pharma market will see good growth in some sectors, falls in others
The pharmaceutical market in Japan will grow at different rates, depending on sector, according to a recent survey conducted by Fuji Keizai, a Tokyo-based marketing research company. The report covers the current situation and prospects in the therapeutic areas of cardiovascular diseases, infection, antivirals and vaccines.
The market for cardiovascular drugs including the antihypertensives, agents for thrombosis, angina pectoris, cardiac failure and arrhythmia will increase 7.5% to 1,322.6 billion yen ($12.57 billion) in 2016 versus 1,230.0 billion yen in 2007. In 2008, sales of CV drugs are expected to reach 1,235.1 billion yen.
Antihypertensives make up 70% of CV sales
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze